1 Full title:

- 2 ePOCT+ and the medAL-suite: Development of an electronic clinical decision support algorithm and
- 3 digital platform for pediatric outpatients in low- and middle-income countries

4 Short title:

5 Development of ePOCT+ and the medAL-suite

6 Authors:

- 7 Rainer Tan,^{1,2,3} Ludovico Cobuccio,^{1,2} Fenella Beynon,² Gillian Levine,² Nina Vaezipour,² Lameck
- 8 Luwanda,³ Chacha Mangu,⁴ Alan Vonlanthen,⁵ Olga De Santis,^{1,6} Nahya Salim,^{3,7} Karim Manji,⁷ Helga
- 9 Naburi,⁷ Lulu Chirande,⁷ Lena Matata,^{2,3} Method Bulongeleje,⁹ Robert Moshiro,⁷ Andolo Miheso,⁹
- 10 Peter Arimi,¹⁰ Ousmane Ndiaye,¹¹ Moctar Faye,¹¹ Aliou Thiongane,¹¹ Shally Awasthi,¹² Kovid
- 11 Sharma,¹³ Gaurav Kumar,² Josephine Van De Maat,¹⁴ Alexandra Kulinkina,^{2,15} Victor Rwandarwacu,²
- 12 Théophile Dusengumuremyi,² John Baptist Nkuranga,¹⁶ Emmanuel Rusingiza,^{17,18} Lisine Tuyisenge,¹⁷
- 13 Mary-Anne Hartley,¹⁹ Vincent Faivre,⁵ Julien Thabard,⁵ Kristina Keitel^{*2,20} & Valérie D'Acremont^{*1,2}
- 14 *Contributed equally

15 Affiliations:

- 16 1. Digital and Global Health Unit, Unisanté, Centre for Primary Care and Public Health, University of
- 17 Lausanne, Lausanne, Switzerland
- 18 2. Swiss Tropical and Public Health Institute, Basel, Switzerland
- 19 3. Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania
- 20 4. National Institute of Medical Research Mbeya Medical Research Centre, Mbeya, United
- 21 Republic of Tanzania
- Department of Information and Technology, Unisanté, Center for Primary Care and Public Health,
 University of Lausanne, Switzerland
- 24 6. Institute of Global Health, University of Geneva, Geneva, Switzerland
- 25 7. Department of Pediatrics and Child Health, Muhimbili University Health and Allied Sciences
- 26 (MUHAS), Dar es Salaam, United Republic of Tanzania
- 27 8NOTE: ATilstprenainesporataewnesdanite of a Republice of ceanizaby peer review and should not be used to guide clinical practice.

- 28 9. PATH, Nairobi, Kenya
- 29 10. College of Health Sciences, University of Nairobi, Nairobi, Kenya
- 30 11. Department of Pediatrics, Cheikh Anta Diop University, Dakar, Senegal
- 31 12. Department of Pediatrics, King George's Medical University, Lucknow, India
- 32 13. PATH, Lucknow, India
- 33 14. Radboudumc, Department of Internal Medicine and Radboudumc Center for Infectious Diseases,
- 34 Nijmegen, Netherlands
- 35 15. University of Basel, Basel, Switzerland
- 36 16. Department of Paediatrics, King Faisal Hospital, Kigali, Rwanda
- 37 17. University Teaching Hospital of Kigali, Kigali, Rwanda
- 38 18. School of Medicine and Pharmacy, University of Rwanda, Kigali, Rwanda
- 39 19. Intelligent Global Health, Machine Learning and Optimization Laboratory, Swiss Federal Institute
- 40 of Technology (EPFL), Lausanne, Switzerland
- 41 20. Paediatric Emergency Department, Department of Pediatrics, University Hospital Berne, Berne,
- 42 Switzerland
- 43
- 44 Corresponding author:
- 45 Dr. Rainer Tan
- 46 Digital & Global Health Unit
- 47 Unisanté, Centre for Primary Care and Public Health, University of Lausanne
- 48 Lausanne, Switzerland
- 49 Email: rainer.tan@unisante.ch
- 50 Tel: +255 676 020 505
- 51 Keywords: Clinical decision support algorithm, mHealth, digital health, child health, global health,
- 52 fever, antibiotic stewardship, quality of care
- 53
- 54
- 2

55 **ABSTRACT**:

56 Electronic clinical decision support algorithms (CDSAs) have been developed to address high 57 childhood mortality and inappropriate antibiotic prescription by helping clinicians adhere to guidelines. 58 Previously identified challenges of CDSAs include its limited scope, usability, and outdated clinical 59 algorithms. To address these challenges we developed ePOCT+, a CDSA for the care of pediatric 60 outpatients in low- and middle-income settings, and the medical algorithm suite (medAL-suite), a 61 software for the creation and execution of CDSAs. Following the principles of digital development, we 62 aim to describe the process and lessons learnt from the development of ePOCT+ and the medAL-63 suite.

64 In particular, this work outlines the systematic integrative development process in the design and 65 implementation of these tools required to meet the needs of clinicians to improve uptake and quality of 66 care. We considered the feasibility, acceptability and reliability of clinical signs and symptoms, as well 67 as the diagnostic and prognostic performance of predictors. To assure clinical validity, and 68 appropriateness for the country of implementation the algorithm underwent numerous reviews by 69 clinical experts and health authorities from the implementing countries. The digitalization process 70 involved the creation of medAL-creator, a digital platform which allows clinicians without IT skills to 71 easily create the algorithms, and medAL-reader the mobile health (mHealth) app used by clinicians 72 during the consultation. Extensive feasibility tests were done with feedback from end-users of multiple 73 countries to improve the clinical algorithm and medAL-reader software.

74 We hope that the development framework used for developing ePOCT+ will help support the

75 development of other CDSAs, and that the open-source medAL-suite will enable others to easily and

76 independently implement them.

77 AUTHOR SUMMARY


- 78 In accordance with the principles of digital development we describe here the process and lessons
- 79 learnt from the development of ePOCT+, a clinical decision support algorithm (CDSA), and the
- 80 medAL-suite software, to program and implement CDSAs.
- 81 The clinical algorithm was adapted from previous CDSAs in order to address challenges in regards to
- the limited scope of illnesses and patient population addressed, the ease of use, and limited
- 83 performance of specific algorithms. Adaptations and improvements to the clinical algorithm was
- 84 developed based on considerations of what symptoms and signs would be appropriate for primary
- 85 care level health care workers, and how well these clinical elements are at predicting a particular
- 86 disease or severe outcome. We hope that by sharing our multi-stakeholder approach to the
- 87 development of ePOCT+, it can help others in the development of other CDSAs.
- 88 The medAL-creator software was developed to allow clinicians without IT programming experience to
- 89 program the clinical algorithm using a drag-and-drop interface, which we hope allows a wider range of
- 90 health authorities and implementers to develop and adapt their own CDSA. The medAL-reader
- 91 application, deploys the algorithm from medAL-creator to end-users following the usual healthcare
- 92 processes of a consultation.
- 93

95 INTRODUCTION

96 Electronic clinical decision support algorithms (CDSAs) have been implemented in low- and middle-97 income countries (LMICs) in order to address excessive mortality due to poor quality of health care,[1] 98 and antimicrobial resistance due to inappropriate antibiotic prescription.[2-4] Such tools provide 99 guidance through every step of the outpatient consultation to ultimately suggest the diagnosis and 100 management plan based on the inputted symptoms, signs and test results.[5] CDSAs have indeed 101 shown that they help clinicians better adhere to guidelines, [6-8] which results in improved quality of 102 care and, for some, more rational antibiotic prescription.[9, 10] This has, in part led the World Health 103 Organization (WHO) and Member States to prioritize the scale-up of the development and access to 104 digital health technologies.[11, 12]

105 Current CDSAs are not standardized, and concerns have been raised about their limited demographic
106 and clinical scope,[13, 14] their usability,[14, 15] and their static and generic logic based on outdated
107 guidelines that are unable to adapt to new evidence, evolving epidemiology, or changing resources.
108 These challenges may contribute to variable uptake of CDSAs,[15-17] and suboptimal performance
109 when implemented.[8, 18]

In order to address these challenges, and build on the experience of previous CDSAs by our group,[9, 10] and others,[5, 8] we developed the CDSA ePOCT+, and a supporting digital software to create and execute CDSAs, the medAL-*suite*. ePOCT+ is currently being implemented in several hundred health facilities within the context of implementation studies in Tanzania, Rwanda, Senegal, Kenya and India. Following the principles of digital development and guidance on CDSAs,[19-21] we aim to transparently share the rationale, strategy, and lessons learnt from this development process (figure 1).



- Figure 1: Overall development process of ePOCT+ requiring multiple feedback loops
- The development process of ePOCT+ was an iterative process. We first defined the scope, then developed the
- algorithm (decision tree logic), followed by expert review with relevant stakeholders, the digitalization, and finally
- piloting and testing. Each stage resulted in multiple feedback loops to refine the end product.

124 METHODS

125

126 Scope

127 Compared to our previous generation CDSAs,[5, 9, 10] the target level of care (primary care health

- 128 facilities), and target users (mostly nurses and non-physician clinicians) remain the same. However,
- 129 the target patient population was expanded from 2 months to 5 years, to also cover young infants

below 2 months, and in some countries children 5 years up to 15 years.

131

The expanded target population age group was enlarged to address young infants (<2 months) who are at highest risk of mortality,[22] and children aged 5-15 years whom are often neglected in international and national policies resulting in a slower decrease in mortality in LMICs compared to children under 5 years.[23] This expanded age group may help address the challenge of uptake by avoiding the need for clinicians to change tools when managing children of different age groups.

The scope of illnesses covered was also expanded in response to the frustration of clinicians using CDSAs who were not able to reach specific illnesses.[13, 15] Expanding the scope allowed for the integration of common illnesses covered by other national clinical guidelines to which clinicians are expected to adhere, and to provide more opportunity for antibiotic stewardship when providing management guidance for specific illnesses.

Three major criteria were considered when expanding the scope of illnesses: 1) Incidence of
presenting symptoms and diagnoses; 2) Morbidity, mortality, and outbreak potential; and 3) Capacity
to diagnose and manage specific conditions at the primary care level.

Additional conditions were identified through: 1) national guidelines; 2) fever aetiology studies; 3)
national health surveys; 4) chief complaints from primary care outpatient studies; 5) clinical expert
review teams from the implementation countries; 6) interviews with end user clinicians; and 6)
observation of consultations at primary care health facilities (S1 Appendix). Examples of notable
additions for the Tanzanian algorithm include trauma, urinary tract infection, and abdominal pain that
can account for 4.3 – 21.6%,[24] 5.9 – 19.7%,[24-26] and 4.6 – 23%[10, 25] of outpatient

151 consultations respectively.

152 Clinical algorithm

The target users (mostly nurses and non-physician clinicians), and setting (primary care health facilities) were important considerations when identifying the guidelines and evidence to develop the algorithm. Previously validated algorithms,[10] and the WHO Integrated Management of Childhood Illnesses (IMCI) chart booklets formed the backbone of the algorithm.[27] To support the expanded clinical scope, we turned to national guidelines to ensure adaptation to the local epidemiology, resources, and setting. For conditions not covered by these guidelines, or where guidelines were not sufficiently detailed, the addition of peer-reviewed literature and other international guidelines were

160 required.

161 In order to transform narrative guidelines into Boolean decision tree logic algorithms, considerable 162 interpretation was needed. The guiding principles for this process were derived from the properties to 163 consider in the screening and diagnosis of a disease by Sackett and colleagues, [28] the target product 164 profile (TPP) for CDSAs as defined by experts in the field, [20] and guidance on appropriate diagnostic 165 and prognostic model development. [29] These include consideration of: a) the feasibility, acceptability, 166 and reliability of clinical elements assessed at the primary care level, b) the diagnostic and prognostic 167 value of individual and combined predictors, c) the sensitivity and specificity in relation to the severity 168 and pre-test probability of the condition in the target population, and d) the overall clinical impression 169 of the patient by the clinician.

170 a) Feasibility, acceptability, and reliability of predictors

171 If clinical algorithms are to be adequately utilized, the signs and symptoms used to reach a diagnosis 172 must be feasible, acceptable and reliable when assessed by end-users. These properties were 173 evaluated based on the results of several assessments: primarily an international Delphi study on 174 predictors of sepsis in children, [30] a systematic review on triage tools in low-resource settings, [31] 175 signs and symptoms included in established guidelines for primary care health care workers such as 176 IMCI,[27] interviews with clinicians, observation of routine consultations, a Delphi survey among 30 177 Tanzanian health care workers (S2 Appendix), as well as subsequent feasibility tests observing 178 clinicians using the CDSA on real and fictional cases. Notable findings from this process led to the 179 omission of a pain score, capillary refill time, the assessment of cool peripheries, and weak and fast 180 pulse, as they were deemed neither feasible nor reliable to be assessed at the primary care level.

181 b) Diagnostic and prognostic value of predictors


182 In the absence of validated diagnostic models for each diagnosis, we assessed individual diagnostic 183 and prognostic factors to help guide the development of ePOCT+. Diagnostic studies derived from the 184 population and setting of interest were preferred, [32, 33] as those developed from other settings often 185 perform worse.[34] However, diagnostic predictors notably those predicting 'serious bacterial 186 infection', often have low sensitivity, lack reference tests to confirm bacterial origin, and ignore serious 187 infections caused by viral diseases.[35, 36] Prognostic studies are often better suited to develop 188 clinical algorithms in order to understand which children are at risk of developing severe disease, 189 regardless of the aetiology, to improve patient outcomes and reduce resource misallocation. [37-39] A 190 systematic review of predictors of severe disease in febrile children presenting from the community 191 helped identify useful clinical feature to be integrated within ePOCT+,[34] however few studies 192 occurred at the primary care level. To address this gap we performed an exploratory analysis of 193 clinical elements used in two CDSAs evaluated in Tanzania to predict clinical failure (S3 Appendix). 194 This analysis found IMCI danger signs, severe general appearance, mid-upper arm circumference 195 <12.5cm, oxygen saturation <90%, respiratory distress, and signs of anaemia and dehydration to be 196 good predictors of clinical failure. Specific subgroup analyses on our previous generation CDSA 197 provided further support for maintaining or modifying specific algorithm branches, particularly the 198 inclusion of C-reactive Protein (CRP) point-of-care tests that helped safely reduce antibiotic 199 prescription and improve confidence in management.[40, 41]

200 c) <u>Sensitivity and specificity of algorithm branches in relation to severity and pre-test probability of</u> 201 <u>condition</u>

202 When constructing the algorithm, it was important to first identify children presenting with a severe 203 condition, and only then use more specific branches to distinguish conditions requiring specific 204 treatment from self-limiting illnesses requiring only supportive care (figure 2). Predictors of severe 205 conditions need to be sufficiently sensitive to guide interventions to reduce morbidity and mortality. 206 However if this high sensitivity comes at the cost of reduced specificity, it can result in over-referral, 207 misallocation of limited health care resources, and excess antibiotic prescription.[37] While this 208 concept was considered within the development of the algorithm, most predictors and models studied 209 lacked sufficient sensitivity and specificity to appropriately meet these requirements at the primary 210 care level, thus emphasizing the need for better predictors and models.[34, 37]

211 Once a severe condition has been excluded, restricting antimicrobial prescriptions can be more safely 212 integrated given the lower risk of clinical failure. Understanding the pre-test probability (disease 213 prevalence) of the disease guides us on the level of specificity needed for the corresponding 214 predictors to be included in the algorithm. In the outpatient settings, few non-severe children above 2 215 months have a condition requiring antibiotics.[10, 26] As such, using the principles of Bayes' 216 theorem,[42] an algorithm for a condition of low prevalence requires a higher likelihood ratio to have a 217 similar post-test probability than a condition with a higher prevalence. Within ePOCT+, C-Reactive 218 Protein (CRP) test is integrated in several branches of the algorithm to increase specificity/likelihood 219 ratio when the pre-test probability of requiring antibiotics is low. However, the pre-test probability of 220 requiring antibiotics may increase in a child with comorbidities, and therefore a lower CRP cut-off can 221 be used to increase sensitivity and reach the same post-test probability.

222



223

Figure 2: Considerations for the required sensitivity and specificity of combined predictors based on the severity and the pre-test probability (disease prevalence) of the condition

Health care workers are confronted with two major questions at primary care health facilities: 1) Does the child need to be referred? For which an algorithm must evaluate sensitivity and specificity in relation to the severity of disease. 2) Does the child require specific treatment (most often an antibiotic)? For which the disease prevalence of a bacterial illness needs to be considered when evaluating the sensitivity and specificity of such an algorithm.

230

231 d) Integrating overall clinical impression

232 The overall clinical impression of a healthcare worker plays an important part of the diagnostic 233 process,[43] and may sometimes better identify serious conditions compared to isolated symptoms 234 and signs.[44, 45] As blindly following CDSA recommendations runs the risk of neglecting nuanced 235 clinical observations or patient-initiated elements, we incorporated clinical impression in the algorithm 236 to better preserve these skills.[46] More generally, it also shows a respect and consideration for the 237 clinician's judgment and allows the tools to be more participatory; including the clinician in the 238 interpretation and responsibility of the decision. As such, attempts were made to combine multiple 239 clinical elements into one question utilizing clinical impression. This approach was used to help identify 240 children who need a referral or antibiotics, such as "Severe difficult breathing needing referral", a 241 criteria similar to that proposed by the British Thoracic Society, [47] and "well/unwell appearing child", 242 often used in children with fever without apparent source.[35, 48] Highlighting in the application that 243 this response will result in a recommendation of referral, aims to help clinicians understand the impact 244 of their selection, and thus improve both the sensitivity and specificity. Such composite elements 245 reduce the number of questions prompted by the CDSA, and speeds up the process; an important 246 consideration for uptake. Nevertheless, the diagnostic and prognostic value of the overall clinical 247 impression of primary care clinicians in LMIC settings is not well understood, and further research is 248 needed to understand how helpful these types of elements are when integrated within ePOCT+.

249

250 Adapting and validating the medical content

251 ePOCT+ was first developed for Tanzania, where the prior generation of the algorithm was validated 252 in a randomized-controlled trial.[10] Following the expansion and adaptation of the content described 253 above, the algorithm was internally reviewed by 13 clinicians from 6 medical institutions with good 254 understanding of CDSAs; 5 working in Tanzania, and the other 8 with experience working in LMICs. 255 The ePOCT+ algorithm for Rwanda, Senegal, Kenya and India were then each drafted, with rounds of 256 internal review, by small development teams composed of clinical algorithm development specialists, 257 and national child health experts based on country-specific objectives, guidelines, and epidemiology, 258 using the first algorithm as a scaffold.

In each country, the ePOCT+ algorithm was reviewed by a technical panel from the ministry of health
 or an independent clinical expert group (usually with ministry of health representatives). The panels
 were asked to assess the algorithm in terms of clinical validity, feasibility in primary care, scope of

illnesses, and consistency with national policy and guidelines. The process of validation varied slightly
 in each country according to national decision-making mechanisms, but all included written feedback,
 individual and group meetings.

265 Certain algorithm branches were highlighted for group discussion; especially those with novel content, 266 those for which significant interpretation was required from national guidelines, and any branches with 267 queries or comments from panel members. For the algorithms with more novel content, more formal 268 decision processes were used.

269 Following the internal and external reviews, further modifications were made during the digitalization

270 process, and feasibility tests, including feedback and review from end-users. For each major change

proposed, the modification was communicated with the group to allow subsequent feedback and final

272 approval by health authorities

273 Digitalization of ePOCT+ and development of the medAL-suite

274 We performed a landscaping review of existing CDSA software with respect to user interface, open

source, data management, ease of programming and interpretation of clinical algorithms, and

276 operability in target health facilities. Since none of the available software packages met our

277 requirements, we developed the medAL-suite software following the requirements of the target product


278 profile for CDSAs.[20] medAL-creator allows clinical experts to design the clinical content and logic of

the algorithm, while medAL-reader is an Android based interface to execute the algorithm to end-user

280 clinicians (figure 3). Both software were developed collaboratively between the clinicians, IT

281 programmers, end-users via feedback from field tests, and health authorities from the implementation

282 countries.



283

284 Figure 3: medAL-creator and medAL-reader

285 A) medAL-creator and its "drag and drop" user interface to design the clinical algorithm. For each clinical element 286 a description and/or photo can be included to assist the end-user using medAL-reader; B) medAL-reader the 287 android based application to collect the medical history, exposures, symptoms, signs and tests, and then propose 288 the appropriate diagnosis and management.

289

290 The World Health Organization (WHO) have recently proposed the SMART guidelines to provide 291 guidance and structure to translate the narrative guidelines (Layer 1), to semi-structured "human 292 readable" decision trees and digital adaptation kits (Layer 2), to computer/machine readable structured 293 algorithms (Layer 3), to the executable form of the software (Layer 4), and finally dynamic algorithms 294 that are trained and optimised to local data (Layer 5).[49] Each "translation" between layers is prone to 295 interpretation and error, especially when each layer is developed by different actors and continuously 296 adapted. To reduce error in interpretation, a major feature of medAL-creator is to allow the 297 "computer/machine readable" structured algorithms to be "human readable", thus merging Layers 2 298 and 3. medAL-creator features a "drag and drop" user interface and automatic terminology/code set 299 enabling the clinicians with no programming knowledge to create and review the algorithm. medAL-300 reader is then able to automatically convert the algorithm from medAL-creator for use at point-of-care. 301 medAL-reader, was designed based on our previous experiences of CDSA interfaces, [7, 10] and 302 expert guidance on successful strategies in order for the application to be intuitive to use with limited 303 training, to align with normal workflows at primary care health facilities, and encourage user 304 autonomy.[20, 50, 51]

305 Validation tests and user-experience evaluations

306 Validation tests were performed for each diagnosis to assure that the inputted data within medAL-307 creator were processed correctly into the expected output data on medAL-reader. This included 308 automated unit and integration testing, as well as automated non-regression testing by medAL-creator, 309 and manual verification of medication posology for all drugs according to weight and age of the 310 patient. All issues were reviewed by a clinical and IT team to correct the problems. While such tests 311 are encouraged by the CDSA TPP,[20] since CDSAs are not considered a "software as a medical 312 device "by the Food and Drug Administration (FDA)[52] or European Medical Device Coordination 313 Group,[53] these tests are not legally required.

314 The ePOCT+ tool underwent numerous rounds of testing in the field, from desk-based reviews

focusing on user interface and analytical validation; to end-user testing evaluating user experience,

316 acceptability, and clinical applicability; to finally assessing integrated testing in real-life conditions. All

317 user experience feedback was reviewed by a team including both clinical and IT specialists, while all

318 clinical content modifications were approved by both the internal and external review panels.

319

320 Ethics

321 Activities related to the development and piloting of ePOCT+ and the medAL-suite were done within 322 the studies of DYNAMIC and TIMCI, for which approval was given from each country of 323 implementation. The study protocol and related documents were approved by the institutional review 324 boards of the Ifakara Health Institute in Tanzania (IHI/IRB/No: 11-2020 and 49-2020), the National 325 Institute for Medical Research in Tanzania (NIMR/HQ/R.8a/Vol. IX/3486 and NIMR/HQ/R.8a/Vol. 326 IX/3583), the National Ethics Committee of Rwanda (752/RNEC/2020), the Comité National d'Ethique 327 pour la Recherche en Santé of Senegal (SEN20/50), the University of Nairobi Ethics and Research 328 Committee in Kenya (UON/CHS/TIMCI/1/1), the King George's Medical College Institutional Ethics 329 Committee in India (103rd ECM IC/P2), the Indian Council of Medical Research (2020-9753), the 330 cantonal ethics review board of Vaud, Switzerland (CER-VD 2020-02800 & CER-VD 2020-02799), 331 and the WHO Ethics Review Committee (ERC.0003405 & ERC.0003406). Written informed consent 332 was obtained from all parents or guardians of children involved in the piloting of ePOCT+ and medAL-333 Reader. No informed consent was obtained from health care workers involved in the development and 334 refinement of the tools.

335 The exploratory analysis of predictors from the 2014 ePOCT study received approval of the study

336 protocol and related documents by the institutional review boards of the Ifakara Health Institute and

- 337 the National Institute for Medical Research in Tanzania (NIMRrHQ,R.8a,/trl'Voll . 789), by the
- 338 Ethikkommission Beider Basel in Switzerland (EKNZ UBE 15/03), and the Boston Children's Hospital
- 339 ethical review board. Written informed consent was obtained from all parents or guardians.
- 340

341 RESULTS

- 342 The ePOCT+ clinical algorithm and supporting evidence for each country of implementation can be
- found on the websites of the <u>DYNAMIC</u> and <u>TIMCI</u> studies that are implementing ePOCT+. The major
- 344 features of medAL-*Creator* and medAL-*Reader* are summarized in the supplementary material (S4
- 345 Appendix), including the requirements defined by the CDSA target product profile (S5 Appendix).
- 346 The feasibility tests of ePOCT+ were conducted in 20 health facilities, leading to numerous
- 347 modifications (Table 1). The improved algorithm was then piloted with over 2000 consultations before
- 348 officially starting the clinical validation studies in the five countries of implementation.
- 349

Issue	Description + context	Modifications
CDSA impractical in	Child with convulsions was brought into the	Emergency button integrated so
emergency situations	consultation room interrupting the current	that emergency management
	consultation. The clinician stopped using the	guidance can easily be accessed at
	tablet and managed the child providing the	any point of the algorithm.
	incorrect antibiotic class and dose	
Understanding	Why a patient reached a specific diagnosis	To improve understanding, and to
algorithm branches	was not always well understood by clinicians	have medAL-reader as a learning
		tool, efforts were made to simply
		present the decision tree logic for
		individual diagnostic and syndromic
		branches of the algorithm.
Some medicines not	Sometimes medicines recommended by	Provide alternative medicines for
available at health	national guidelines were not available	most conditions in case the
		recommended one is not available.

facilities due to stock-		
outs		
Misunderstanding of	The labelling of some symptoms and signs	Modification of labelling of some
the labelling of some	were not well understood by the clinician	elements, clarification provided in
clinical elements		the information button, and
		translation to local language
Some clinical signs not	Many clinicians did not always measure	Provide options to not measure
measured, especially	required clinical signs (anthropometrics,	some clinical signs and rather
when patients are	temperature, respiratory rate) and could thus	estimate the values (with warning
many	not continue with the algorithm	that this is sub-optimal) to limit
		clinicians being 'stuck', to
		discourage false information to be
		entered, and to provide mentorship
		to those not measuring these signs
No clear identification	Clinicians selected variables that resulted in	Elements that result in the diagnosis
of symptoms and signs	a severe diagnosis, parenteral antibiotics,	of a severe disease and referral are
that always result in	and referral, for which the clinician did not	highlighted
severe disease /	agree with.	
referral		

351

352 **DISCUSSION**

353 ePOCT+ was derived from existing evidence and clinical validation field studies from previous 354 generation CDSAs.[7, 9, 10] It is now being further validated in several large clinical studies. Following 355 established development protocols, attempts were made to ensure a transparent development 356 process, multi-stakeholder collaboration, and end-user feedback. [20, 21, 54, 55] Specifically, aligning 357 the development process of ePOCT+ and specifications of medAL-reader to the requirements of the 358 Target Product Profile for CDSAs was helpful to better meet the needs of end users in terms of quality, 359 safety, performance and operational functionality.[20]. Nonetheless, there are several limitations and 360 challenges with the development process and end-result of ePOCT+ and the medAL-suite, for which 361 ongoing modifications and improvements will be required.

362 Firstly, while efforts were made to improve the performance of the algorithm, there was often a

363 reliance on clinical guidelines which may not always be founded on the best/latest/highest quality

364 evidence, or applicable to low resource primary care settings.[56] [57] Furthermore, they require 365 significant interpretation to transform into algorithms. Digital Adaptation Kits (DAKs) to guide 366 implementers in how to interpret narrative guidelines to transform into digital platforms are currently 367 being developed by the World Health Organization and should help address this challenge in the 368 future.[49, 58] Often supplementary evidence was needed to complement national and international 369 guidelines. This evidence should ideally be identified through systematic reviews, [59] however those 370 are not always feasible. Leveraging existing evidence databases as done by another CDSA may be a 371 more feasible method to avoid biases in identifying supporting evidence.[60] Among the supporting 372 evidence identified, there was a paucity of evidence for conditions specific to older children above 5 373 years, prognostic studies in the primary care setting, and diagnostic studies for conditions other than 374 serious bacterial infection and pneumonia. Evaluating the prognostic and diagnostic value of 375 predictors and models used in ePOCT+ during the ongoing validation studies will help to develop more 376 efficient and better performing algorithms optimised for the target population.[49, 61]

377 Many modifications to ePOCT+ and medAL-reader compared to previous generation CDSAs were 378 implemented in order to help improve uptake, addressing previously shared concerns such as limited 379 scope, and ease of use. medAL-reader was specifically designed to follow normal healthcare worker 380 workflows, however the introduction of other digital tools such as electronic medical records hinder 381 these processes. As an example, it is estimated that there are over 160 digital health or health-related 382 systems in Tanzania.[62] While efforts are currently being made to harmonize processes so that 383 different digital systems can complement each other, rather than creating additional work, this has not 384 yet been achieved. It is important to note, that while ePOCT+ and medAL-reader may address some 385 challenges to uptake, there are many extrinsic and intrinsic factors that are not addressed, such as the 386 low perceived value of following guidelines, and lack of motivation partly related to poor

387 remuneration.[15, 63]

388 The digitalization process allows for increased complexity in the algorithm compared to paper

389 guidelines. However, this complexity may limit the understanding by healthcare workers.

390 Understanding how a diagnosis and treatment plan is reached is fundamental to clinical and patient

autonomy, important for continued learning, and for fostering trust in any algorithm.[64-66] Efforts were

392 made to present simple decision tree logic for each diagnosis. Nevertheless, the optimal method of

- 393 presentation of algorithm branches to assure understanding by primary care level healthcare workers
- 394 should be further explored.

396 CONCLUSION

- 397 ePOCT+ aims to improve clinical care of sick children in LMICs, notably by reducing unnecessary
- antibiotic prescription. We hope that the strong stakeholder involvement, the expanded scope of the
- 399 clinical algorithm, and the novel software of the medAL-suite will result in high uptake, trust and
- 400 acceptability. Widespread implementation will provide opportunity for dynamic and targeted
- 401 refinements to the clinical content to improve the performance of the algorithm. We hope that the
- 402 easy-to-use platform of the medAL-suite, and the framework used to develop ePOCT+ will allow
- 403 health authorities and local communities to be able to take ownership of ePOCT+ or their own clinical
- 404 algorithm for future adaptations and developments. Future success however, is contingent on the
- 405 harmonization with national health management information systems and other digital systems.

406

408 **Declaration of interests:**

409 We declare no competing interests.

410

411 Funding

- 412 This work took place within the framework of the DYNAMIC project that is funded by the Fondation
- 413 Botnar, Switzerland (grant n°6278) as well as the Swiss Development Cooperation (grant n°7F-
- 414 10361.01.01) received by VDA. The TIMCI project funded by UNITAID (grant n°2019-35-TIMCI)
- 415 received by VDA allowed for adapting of ePOCT+ or the medAL-suite software to Senegal, Kenya and
- 416 India. The funders had no role in the development of ePOCT+ or the medAL-suite software, data
- 417 collection, analysis, nor did they have a role in the decision to publish, or preparation of this
- 418 manuscript.

419

420 Acknowledgements:

Emmanuel Barchichat, Alain Fresco, and Quentin Girard from Wavemind for the IT programming of medal-creator and medal-reader software. Martin Norris, Lisa Cleveley, Dr Sabine Renggli, Ibrahim Mtabene, Peter Agrea and Dr Godfrey Kavishe for the medAL-reader tests and suggestions for improvements to both medal-reader and medal-creator. Cecile Trottet for the statistical support. The many health care workers providing feedback on the tool, patients and caretakers involved with pilot and feasibility testing. Dr Arjun Chandna and Janet Urquhart for helpful comments on the manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2022.09.02.22279524; this version posted September 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

428 REFERENCES

429 Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality 1. 430 due to low-quality health systems in the universal health coverage era: a systematic analysis 431 of amenable deaths in 137 countries. The Lancet. 2018;392(10160):2203-12. doi: 432 10.1016/S0140-6736(18)31668-4.

433 Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. 2. 434 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The 435 Lancet. 2022. doi: 10.1016/S0140-6736(21)02724-0.

436 Fink G, D'Acremont V, Leslie H, Cohen J. Antibiotic use among children under five in 3. 437 low and middle income countries: Evidence from nationally representative facility and 438 household surveys. Lancet Infectious Diseases. in press.

439 van de Maat J, De Santis O, Luwanda L, Tan R, Keitel K. Primary Care Case 4. 440 Management of Febrile Children: Insights From the ePOCT Routine Care Cohort in Dar es 441 Salaam, Tanzania. Frontiers in pediatrics. 2021;9(465). doi: 10.3389/fped.2021.626386.

442 Keitel K, D'Acremont V. Electronic clinical decision algorithms for the integrated 5. 443 primary care management of febrile children in low-resource settings: review of existing 444 tools. Clinical microbiology and infection : the official publication of the European Society of 445 Clinical Microbiology and Infectious Diseases. 2018;24(8):845-55. Epub 2018/04/24. doi: 446 10.1016/i.cmi.2018.04.014. PubMed PMID: 29684634.

447 Bernasconi A, Crabbé F, Raab M, Rossi R. Can the use of digital algorithms improve 6. quality care? An example from Afghanistan. PLoS One. 2018;13(11):e0207233-e. doi: 448 449 10.1371/journal.pone.0207233. PubMed PMID: 30475833.

450 7. Rambaud-Althaus C, Shao A, Samaka J, Swai N, Perri S, Kahama-Maro J, et al. 451 Performance of Health Workers Using an Electronic Algorithm for the Management of 452 Childhood Illness in Tanzania: A Pilot Implementation Study. The American journal of tropical 453 medicine and hygiene. 2017;96(1):249-57. Epub 2017/01/13. doi: 10.4269/ajtmh.15-0395. 454 PubMed PMID: 28077751; PubMed Central PMCID: PMCPMC5239703.

Sarrassat S, Lewis JJ, Some AS, Somda S, Cousens S, Blanchet K. An Integrated 455 8. 456 eDiagnosis Approach (IeDA) versus standard IMCI for assessing and managing childhood 457 illness in Burkina Faso: a stepped-wedge cluster randomised trial. BMC health services 458 research. 2021;21(1):354-. doi: 10.1186/s12913-021-06317-3. PubMed PMID: 33863326.

459 Shao AF, Rambaud-Althaus C, Samaka J, Faustine AF, Perri-Moore S, Swai N, et al. 9. 460 New Algorithm for Managing Childhood Illness Using Mobile Technology (ALMANACH): A 461 Controlled Non-Inferiority Study on Clinical Outcome and Antibiotic Use in Tanzania. PLoS 462 One. 2015;10(7):e0132316. Epub 2015/07/15. doi: 10.1371/journal.pone.0132316. PubMed 463 PMID: 26161535; PubMed Central PMCID: PMCPMC4498627.

464 Keitel K, Kagoro F, Samaka J, Masimba J, Said Z, Temba H, et al. A novel electronic 10. 465 algorithm using host biomarker point-of-care tests for the management of febrile illnesses in 466 Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial. PLoS medicine. 467 2017;14(10):e1002411. Epub 2017/10/24. doi: 10.1371/journal.pmed.1002411. PubMed 468 PMID: 29059253; PubMed Central PMCID: PMCPMC5653205.

469 11. World Health Organization. WHO guideline: recommendations on digital interventions 470 for health system strengthening. Geneva: 2019 Contract No.: Licence: CC BY-NC-SA 3.0 471 IGO.

472 12. United Republic of Tanzania: Ministry of Health CD, Gender, Elderly and Children. 473 Digital Health Strategy. Tanzania: 2019.

474 Bessat C, Zonon NA, D'Acremont V. Large-scale implementation of electronic 13. 475 Integrated Management of Childhood Illness (eIMCI) at the primary care level in Burkina 476 Faso: a qualitative study on health worker perception of its medical content, usability and 477 impact on antibiotic prescription and resistance. BMC public health. 2019;19(1):449. Epub 478 2019/05/01. doi: 10.1186/s12889-019-6692-6. PubMed PMID: 31035968; PubMed Central 479 PMCID: PMCPMC6489291. 480 Mitchell M, Getchell M, Nkaka M, Msellemu D, Van Esch J, Hedt-Gauthier B. 14.

481 Perceived Improvement in Integrated Management of Childhood Illness Implementation medRxiv preprint doi: https://doi.org/10.1101/2022.09.02.22279524; this version posted September 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

through Use of Mobile Technology: Qualitative Evidence From a Pilot Study in Tanzania.
Journal of Health Communication. 2012;17(sup1):118-27. doi:

484 10.1080/10810730.2011.649105.

Shao AF, Rambaud-Althaus C, Swai N, Kahama-Maro J, Genton B, D'Acremont V, et
al. Can smartphones and tablets improve the management of childhood illness in Tanzania?
A qualitative study from a primary health care worker's perspective. BMC health services
research. 2015;15:135-. doi: 10.1186/s12913-015-0805-4. PubMed PMID: 25890078.

489 16. Jensen C, McKerrow NH, Wills G. Acceptability and uptake of an electronic decision490 making tool to support the implementation of IMCI in primary healthcare facilities in KwaZulu491 Natal, South Africa. Paediatr Int Child Health. 2020;40(4):215-26. Epub 2019/11/30. doi:
492 10.1080/20469047.2019.1697573. PubMed PMID: 31779539.

- 493 17. Jensen C, McKerrow NH. The feasibility and ongoing use of electronic decision
 494 support to strengthen the implementation of IMCI in KwaZulu-Natal, South Africa. BMC
 495 Pediatrics. 2022;22(1):80. doi: 10.1186/s12887-022-03147-y.
- Bernasconi A, Crabbé F, Adedeji AM, Bello A, Schmitz T, Landi M, et al. Results from
 one-year use of an electronic Clinical Decision Support System in a post-conflict context: An
 implementation research. PLoS One. 2019;14(12):e0225634. Epub 2019/12/04. doi:
 10.1371/journal.pone.0225634. PubMed PMID: 31790448; PubMed Central PMCID:
 PMCPMC6886837.
- Waugaman A. From principle to practice: implementing the principles for digital
 development. Proceedings of the Principles for Digital Development Working Group. 2016;4.
 20. Pellé KG, Rambaud-Althaus C, Acremont V, Moran G, Sampath R, Katz Z, et al.
 Electronic clinical decision support algorithms incorporating point-of-care diagnostic tests in
 low-resource settings: a target product profile. BMJ Global Health. 2020;5(2):e002067. doi:
- 506 10.1136/bmjgh-2019-002067.
 507 21. Ansermino JM, Wiens MO, Kissoon N. Evidence and Transparency are Needed to
 508 Develop a Frontline Health Worker mHealth Assessment Platform. 2019;101(4):948-. doi:
- 509 <u>https://doi.org/10.4269/ajtmh.19-0411a</u>.
- Li Z, Karlsson O, Kim R, Subramanian SV. Distribution of under-5 deaths in the
 neonatal, postneonatal, and childhood periods: a multicountry analysis in 64 low- and middleincome countries. Int J Equity Health. 2021;20(1):109-. doi: 10.1186/s12939-021-01449-8.
 PubMed PMID: 33902593.
- Masquelier B, Hug L, Sharrow D, You D, Hogan D, Hill K, et al. Global, regional, and
 national mortality trends in older children and young adolescents (5–14 years) from 1990 to
 2016: an analysis of empirical data. The Lancet Global Health. 2018;6(10):e1087-e99. doi:
 https://doi.org/10.1016/S2214-109X(18)30353-X.
- 518 24. McHomvu E, Mbunda G, Simon N, Kitila F, Temba Y, Msumba I, et al. Diagnoses 519 made in an Emergency Department in rural sub-Saharan Africa. Swiss Med Wkly.
- 520 2019;149:w20018. Epub 2019/02/05. doi: 10.4414/smw.2019.20018. PubMed PMID:
 521 30715723.
- 522 25. Hercik C, Cosmas L, Mogeni OD, Wamola N, Kohi W, Omballa V, et al. A diagnostic
 523 and epidemiologic investigation of acute febrile illness (AFI) in Kilombero, Tanzania. PLoS
 524 One. 2017;12(12):e0189712-e. doi: 10.1371/journal.pone.0189712. PubMed PMID:
 525 29287070.
- D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Maro J, et al.
 Beyond malaria--causes of fever in outpatient Tanzanian children. The New England journal
 of medicine. 2014;370(9):809-17. Epub 2014/02/28. doi: 10.1056/NEJMoa1214482. PubMed
 PMID: 24571753.
- 530 27. World Health Organization. IMCI chart booklet. Geneva: 2014.
- 531 28. Sackett DL, Holland WW. Controversy in the detection of disease. Lancet.
- 532 1975;2(7930):357-9. Epub 1975/08/23. doi: 10.1016/s0140-6736(75)92790-7. PubMed
- 533 PMID: 51154.
- 534 29. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et 535 al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or
- 536 Diagnosis (TRIPOD): Explanation and Elaboration. Annals of internal medicine.
- 537 2015;162(1):W1-W73. doi: 10.7326/M14-0698 %J Annals of Internal Medicine.
 - 22

medRxiv preprint doi: https://doi.org/10.1101/2022.09.02.22279524; this version posted September 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

538 30. Fung JST, Akech S, Kissoon N, Wiens MO, English M, Ansermino JM. Determining
539 predictors of sepsis at triage among children under 5 years of age in resource-limited
540 settings: A modified Delphi process. PLoS One. 2019;14(1):e0211274. Epub 2019/01/29.
541 doi: 10.1371/journal.pone.0211274. PubMed PMID: 30689660; PubMed Central PMCID:
542 PMCPMC6349330.
543 31. Hansoti B, Jenson A, Keefe D, De Ramirez SS, Anest T, Twomey M, et al. Reliability

and validity of pediatric triage tools evaluated in Low resource settings: a systematic review.
BMC Pediatrics. 2017;17(1):37. doi: 10.1186/s12887-017-0796-x.

- 546 32. Erdman LK, D'Acremont V, Hayford K, Rajwans N, Kilowoko M, Kyungu E, et al.
 547 Biomarkers of Host Response Predict Primary End-Point Radiological Pneumonia in
 548 Tanzanian Children with Clinical Pneumonia: A Prospective Cohort Study. PLoS One.
 549 2015;10(9):e0137592. Epub 2015/09/15. doi: 10.1371/journal.pone.0137592. PubMed PMID:
 550 26366571; PubMed Central PMCID: PMCPMC4569067.
- 33. De Santis O, Kilowoko M, Kyungu E, Sangu W, Cherpillod P, Kaiser L, et al.
 Predictive value of clinical and laboratory features for the main febrile diseases in children
 living in Tanzania: A prospective observational study. PLoS One. 2017;12(5):e0173314.
 Epub 2017/05/04. doi: 10.1371/journal.pone.0173314. PubMed PMID: 28464021; PubMed
 Central PMCID: PMCPMC5413055.
- S4. Chandna A, Tan R, Carter M, Van Den Bruel A, Verbakel J, Koshiaris C, et al.
 Predictors of disease severity in children presenting from the community with febrile
 illnesses: a systematic review of prognostic studies. BMJ Glob Health. 2021;6(1). Epub
 2021/01/22. doi: 10.1136/bmjgh-2020-003451. PubMed PMID: 33472837.
- 560 35. Keitel K, Kilowoko M, Kyungu E, Genton B, D'Acremont V. Performance of prediction
 561 rules and guidelines in detecting serious bacterial infections among Tanzanian febrile
 562 children. BMC infectious diseases. 2019;19(1):769-. doi: 10.1186/s12879-019-4371-y.
 563 PubMed PMID: 31481123.
- 36. Oostenbrink R, Thompson M, Steyerberg EW. Barriers to translating diagnostic
 research in febrile children to clinical practice: a systematic review. Archives of disease in
 childhood. 2012;97(7):667-72. Epub 2012/01/06. doi: 10.1136/archdischild-2011-300667.
 PubMed PMID: 22219168.
- 37. McDonald CR, Weckman A, Richard-Greenblatt M, Leligdowicz A, Kain KC.
 Integrated fever management: disease severity markers to triage children with malaria and
 non-malarial febrile illness. Malaria Journal. 2018;17(1):353. doi: 10.1186/s12936-018-2488x.
- 572 38. Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic 573 research: Developing a prognostic model. 2009;338:b604. doi: 10.1136/bmj.b604 %J BMJ. 574 Chandna A, Osborn J, Bassat Q, Bell D, Burza S, D'Acremont V, et al. Anticipating 39. 575 the future: prognostic tools as a complementary strategy to improve care for patients with 576 febrile illnesses in resource-limited settings. BMJ Glob Health. 2021;6(7). Epub 2021/08/01. doi: 10.1136/bmjgh-2021-006057. PubMed PMID: 34330761; PubMed Central PMCID: 577 578 PMCPMC8327814.
- Keitel K, Samaka J, Masimba J, Temba H, Said Z, Kagoro F, et al. Safety and
 Efficacy of C-reactive Protein–guided Antibiotic Use to Treat Acute Respiratory Infections in
 Tanzanian Children: A Planned Subgroup Analysis of a Randomized Controlled
 Noninferiority Trial Evaluating a Novel Electronic Clinical Decision Algorithm (ePOCT).
- 583 Clinical Infectious Diseases. 2019;69(11):1926-34. doi: 10.1093/cid/ciz080.
- 584 41. Tan R, Kagoro F, Levine GA, Masimba J, Samaka J, Sangu W, et al. Clinical
 585 Outcome of Febrile Tanzanian Children with Severe Malnutrition Using Anthropometry in
 586 Comparison to Clinical Signs. American Journal of Tropical Medicine and Hygiene.
- 587 2020;102(2):427-35. doi: 10.4269/ajtmh.19-0553. PubMed PMID: WOS:000512881500035.
 588 42. Bayes T. LII. An essay towards solving a problem in the doctrine of chances. By the
- Jayes F. En. An essay towards solving a problem in the doctine of chances. By the
 late Rev. Mr. Bayes, FRS communicated by Mr. Price, in a letter to John Canton, AMFR S.
 Philosophical transactions of the Royal Society of London. 1763;(53):370-418.
- 43. Meredith V, Sandra M, Eamon C, Geoff N, Jonathan S, Matthew S, et al. Experienced
 physician descriptions of intuition in clinical reasoning: a typology. Diagnosis. 2019;6(3):25968. doi: <u>https://doi.org/10.1515/dx-2018-0069</u>.

medRxiv preprint doi: https://doi.org/10.1101/2022.09.02.22279524; this version posted September 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

594 44. Van den Bruel A, Thompson M, Buntinx F, Mant D. Clinicians' gut feeling about 595 serious infections in children: observational study. BMJ : British Medical Journal. 2012;345:e6144. doi: 10.1136/bmj.e6144. 596 597 Dale AP, Marchello C, Ebell MH. Clinical gestalt to diagnose pneumonia, sinusitis, 45. 598 and pharyngitis: a meta-analysis. British Journal of General Practice. 2019;69(684):e444. 599 doi: 10.3399/bjqp19X704297. 600 Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in 46. 601 crisis? BMJ : British Medical Journal. 2014;348:g3725. doi: 10.1136/bmj.g3725. 602 Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic 47. 603 Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2:ii1-23. Epub 2011/10/19. doi: 10.1136/thoraxinl-2011-604 605 200598. PubMed PMID: 21903691. 606 Bleeker SE, Derksen-Lubsen G, Grobbee DE, Donders AR, Moons KG, Moll HA. 48. 607 Validating and updating a prediction rule for serious bacterial infection in patients with fever 608 without source. Acta Paediatr. 2007;96(1):100-4. Epub 2006/12/26. doi: 10.1111/j.1651-609 2227.2006.00033.x. PubMed PMID: 17187613. 610 Mehl G, Tunçalp Ö, Ratanaprayul N, Tamrat T, Barreix M, Lowrance D, et al. WHO 49. 611 SMART guidelines: optimising country-level use of guideline recommendations in the digital 612 age. The Lancet Digital Health. 2021. doi: 10.1016/S2589-7500(21)00038-8. 613 Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An 50. 614 overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ 615 Digit Med. 2020;3:17. Epub 2020/02/13. doi: 10.1038/s41746-020-0221-y. PubMed PMID: 32047862; PubMed Central PMCID: PMCPMC7005290. 616 617 Källander K, Tibenderana JK, Akpogheneta OJ, Strachan DL, Hill Z, ten Asbroek 51. 618 AHA, et al. Mobile health (mHealth) approaches and lessons for increased performance and 619 retention of community health workers in low- and middle-income countries: a review. 620 Journal of medical Internet research. 2013;15(1):e17-e. doi: 10.2196/jmir.2130. PubMed 621 PMID: 23353680. 622 52. US Food and Drug Administration. Software as a Medical Device (SAMD). Clinical 623 Evaluation-Guidance for Industry and Food and Drug Administration Staff. 2017. 624 Eurpoean Commission. Regulation (EU) 2017/745 of the European Parliament and of 53. 625 the Council of 5 April 2017 on Medical Devices, Amending Directive 2001/83/EC, Regulation 626 (EC) No 178/2002 and Regulation (EC) No 1223/2009 and Repealing Council Directives 627 90/385/EEC and 93/42/EEC. Official Journal of the European Union. 2017;L 117/1. 628 Aranda-Jan CB, Mohutsiwa-Dibe N, Loukanova S. Systematic review on what works, 54. what does not work and why of implementation of mobile health (mHealth) projects in Africa. 629 630 BMC public health. 2014;14(1):188. doi: 10.1186/1471-2458-14-188. 631 55. Lampariello R, Ancellin-Panzani S. Mastering stakeholders' engagement to reach 632 national scale, sustainability and wide adoption of digital health initiatives: lessons learnt from 633 Burkina Faso. Fam Med Community Health. 2021;9(3). Epub 2021/06/20. doi: 10.1136/fmch-634 2021-000959. PubMed PMID: 34144970; PubMed Central PMCID: PMCPMC8215243. 635 56. Florez ID, Brouwers MC, Kerkvliet K, Spithoff K, Alonso-Coello P, Burgers J, et al. Assessment of the quality of recommendations from 161 clinical practice guidelines using the 636 637 Appraisal of Guidelines for Research and Evaluation–Recommendations Excellence 638 (AGREE-REX) instrument shows there is room for improvement. Implementation Science. 639 2020;15(1):79. doi: 10.1186/s13012-020-01036-5. 640 57. Maaløe N, Ørtved AMR, Sørensen JB, Sequeira Dmello B, van den Akker T, Kujabi 641 ML, et al. The injustice of unfit clinical practice guidelines in low-resource realities. The 642 Lancet Global Health. 2021. doi: 10.1016/S2214-109X(21)00059-0. 643 58. Tamrat T, Ratanaprayul N, Barreix M, Tuncalp Ö, Lowrance D, Thompson J, et al. Transitioning to Digital Systems: The Role of World Health Organization's Digital Adaptation 644 645 Kits in Operationalizing Recommendations and Interoperability Standards. Global Health: 646 Science and Practice. 2022. doi: 10.9745/GHSP-D-21-00320. 647 59. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P. 648 Guidelines International Network: toward international standards for clinical practice

medRxiv preprint doi: https://doi.org/10.1101/2022.09.02.22279524; this version posted September 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 649 guidelines. Annals of internal medicine. 2012;156(7):525-31. Epub 2012/04/05. doi: 650 10.7326/0003-4819-156-7-201204030-00009. PubMed PMID: 22473437.
- Cornick R, Picken S, Wattrus C, Awotiwon A, Carkeek E, Hannington J, et al. The 651 60.
- 652 Practical Approach to Care Kit (PACK) guide: developing a clinical decision support tool to 653 simplify, standardise and strengthen primary healthcare delivery. BMJ Global Health.
- 654 2018;3(Suppl 5):e000962. doi: 10.1136/bmjgh-2018-000962.
- 655 61. Loftus TJ, Tighe PJ, Ozrazgat-Baslanti T, Davis JP, Ruppert MM, Ren Y, et al. Ideal 656 algorithms in healthcare: Explainable, dynamic, precise, autonomous, fair, and reproducible. PLOS Digital Health. 2022;1(1):e0000006. doi: 10.1371/journal.pdig.0000006. 657
- 658 62. Watts G. The Tanzanian digital health agenda. The Lancet Digital Health.
- 2020;2(2):e62-e3. doi: 10.1016/S2589-7500(20)30005-4. 659
- 660 Lange S, Mwisongo A, Mæstad O. Why don't clinicians adhere more consistently to 63. 661 guidelines for the Integrated Management of Childhood Illness (IMCI)? Soc Sci Med.
- 662 2014;104:56-63. Epub 2014/03/04. doi: 10.1016/j.socscimed.2013.12.020. PubMed PMID: 663 24581062.
- 664 64. World Health Organization. Ethics and governance of artificial intelligence for health: 665 WHO guidance. 2021.
- 666 65. Kundu S. Al in medicine must be explainable. Nature Medicine. 2021;27(8):1328-.
- Amann J, Vetter D, Blomberg SN, Christensen HC, Coffee M, Gerke S, et al. To 667 66.
- 668 explain or not to explain?—Artificial intelligence explainability in clinical decision support
- 669 systems. PLOS Digital Health. 2022;1(2):e0000016. doi: 10.1371/journal.pdig.0000016.
- 670

672 Author contributions:

- 673 Conceptualization of manuscript: RT, VDA, KK; Development of ePOCT+ clinical algorithms: RT, GL,
- 674 NV, FB, LCo, OdS, LL, CM, NS, KM, HN, LCh, VR, TD, JN, ER, LT, LM, MB, RM, AM, PA, ON, MF,
- 675 AT, SA, KS, GK, VDA, KK; Development of medAL-creator and medAL-reader software: VF, AV, RT,
- OdS, FB, LCo, GL, AK, KK, VDA, JT; Delphi survey: JVDM, LL, RT, KK; Statistical analyses: RT, AH;
- 677 Drafted the first draft: RT; Commented and edited the first draft: KK, VDA; Commented on, edited and
- 678 approved the final draft: all
- 679 Supporting information captions
- 680 S1 Appendix: Prevalence of specific symptoms and diagnoses not covered in IMCI from
- 681 Tanzania
- 682 S2 Appendix: Delphi survey on the reliability and feasibility of measurement of symptoms and
- 683 signs
- 684 S3 Appendix: Prognostic value of predictors used in the ePOCT and ALMANACH electronic
- 685 clinical decision support algorithms
- 686 S4 Appendix: Features of the medAL-creator and medAL-reader software as defined by a
- 687 clinical-IT collaboration with end-user feedback
- 688
- 689 S5 Appendix: Evaluation of ePOCT+ based on the characteristics set by the target product
- 690 profile for electronic clinical decision support algorithm as defined by expert consensus
- 691
- 692
- 693